And now, as Dr. Max Gomez of CBS2 reported Wednesday, preliminary studies that have not yet been peer-reviewed are: Johnson & Johnson The vaccine may not be as effective against the delta variant as the other two licensed vaccines.
The J & J vaccine has been administered to more than 13 million people. Many of them have always been somewhat worried about whether they are protected from Delta or Lambda variants. As the recipient Pfizer Or Modana vaccine. That anxiety was exacerbated by the latest New York University study just posted on a site known as the “preprint” site. In other words, it has not been peer-reviewed for publication in scientific journals.
These conclusions differ from the small clinical results announced by J & J earlier this month that a single dose of the vaccine prevented delta even eight months after vaccination.
These differences may be due to a new study examining antibodies in the laboratory compared to the actual immunity of people, including T cell immunity. Peer reviews can help you determine your contribution to protection.
Experts have also shown that the J & J vaccine provides protection against all variants of the coronavirus, perhaps not as much as Pfizer and Modana. What is not yet known is whether mixing and matching different brands is safe as a booster.
However, there are some unpublished, peer-reviewed data from the UK. This suggests that brand mixing and matching (taking Moderna or Pfizer shots after virus shots such as J & J) is not just safe. , But it may also be recommended because it produces a much stronger immune response. But that is certainly not known until the data is submitted and peer reviewed. Hopefully it will happen soon.
A NYU preliminary study suggests that Johnson & Johnson’s COVID vaccine may not be effective against delta variants – CBS New York
Source link A NYU preliminary study suggests that Johnson & Johnson’s COVID vaccine may not be effective against delta variants – CBS New York